Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Calcitonin Gene Related Peptide (CGRP) Therapeutics Report 2016 - Pipeline Review of 5 Companies & 6 Drug Molecules - Research and Markets

Research and Markets
Posted on: 24 Oct 16

Research and Markets has announced the addition of the "Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016" report to their offering.

Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Calcitonin Gene Related Peptide (CGRP) Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception. The molecules developed by Companies in Phase III and Preclinical stages are 3 and 3 respectively.

Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Calcitonin Gene Related Peptide (CGRP) Overview
  3. Therapeutics Development
  4. Pipeline Products for Calcitonin Gene Related Peptide (CGRP) - Overview
  5. Pipeline Products for Calcitonin Gene Related Peptide (CGRP) - Comparative Analysis
  6. Calcitonin Gene Related Peptide (CGRP) - Therapeutics under Development by Companies
  7. Calcitonin Gene Related Peptide (CGRP) - Therapeutics under Investigation by Universities/Institutes
  8. Calcitonin Gene Related Peptide (CGRP) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Calcitonin Gene Related Peptide (CGRP) - Products under Development by Companies
  13. Calcitonin Gene Related Peptide (CGRP) - Products under Investigation by Universities/Institutes
  14. Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
  • Alder Biopharmaceuticals Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Noxxon Pharma AG
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/cmvmvk/calcitonin_gene

View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006353/en/

Business Wire
www.businesswire.com

Last updated on: 24/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.